Management of leukopenia in kidney and pancreas transplant recipients

摘要: Leukopenia is frequently observed in the setting of solid organ transplantation. The risk factors, natural history, and outcomes associated with leukopenia post-transplantation have not been well defined. We retrospectively studied 102 adult kidney and/or pancreas transplant recipients over a one-yr period time. By defining as white blood cell count < or =3000 cells/mm(3) neutropenia an absolute neutrophil =2000/mm(3), combined incidence either was 58% (59/102); first episode occurred at mean 91 d post-transplant. A significant increase found patients who received alemtuzumab induction (42% vs. 9% rabbit anti-thymocyte globulin induction, p 0.05) had rapid steroid withdrawal early post-transplant (44% 16% without withdrawal, 0.05). most common intervention performed for reducing dose mycophenolate mofetil valganciclovir. When granulocyte stimulating factors were used, 3.1 doses needed to successfully manage leukopenia. Although finding our study recipients, there no difference rates infection acute rejection